Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) provides access to the company’s official U.S. regulatory disclosures as a commercial-stage biopharmaceutical and medical dermatology issuer. These documents, filed with the Securities and Exchange Commission, give detailed insight into Arcutis’ financial performance, governance, and progress in developing and commercializing therapies for immune-mediated dermatological diseases and conditions.
Key filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe product revenue from the ZORYVE (roflumilast) franchise, research and development expenses related to atopic dermatitis, plaque psoriasis, seborrheic dermatitis, and pipeline programs, as well as selling, general, and administrative costs tied to commercialization. These reports also summarize risk factors, intellectual property, and other information relevant to Arcutis’ pharmaceutical preparation manufacturing activities.
Current reports on Form 8-K document material events such as quarterly and year-to-date financial results, strategic updates, and changes in the composition of the board of directors. For example, recent 8-K filings describe the release of financial results for specific quarters and the retirement and appointment of directors, including details of compensation arrangements and consulting agreements. Such filings help investors track governance developments and corporate actions in real time.
Investors interested in executive and director compensation, equity awards, and governance policies can review proxy statements and related exhibits, while those monitoring capital structure and financing activities can examine notes in periodic reports and any registration statements or prospectus supplements that may be filed. Filings also confirm that Arcutis’ common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ARQT.
On this page, Stock Titan pairs Arcutis’ raw SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as revenue trends for ZORYVE products, major R&D milestones, and notable risk factor updates. Users can quickly scan AI-generated overviews of Forms 10-K and 10-Q, then drill into the full text for deeper analysis. Real-time ingestion from EDGAR ensures that new 8-Ks, periodic reports, and exhibits appear promptly, while structured views of ownership and transaction data make it easier to follow equity awards and other reportable items disclosed in Arcutis’ filings.
Masaru Matsuda reported Rule 144 sale notices for Arcutis Biotherapeutics common stock. The filing lists sales of 40,638, 3,325 and 1,675 shares in the past three months, and separately lists restricted stock vesting of 6,746, 3,325 and 1,987 shares on the dates shown.
The broker listed is Merrill Lynch and the security trades on NASDAQ. The filing records transaction dates including 02/02/2026, 02/27/2026 and 12/01/2025.
Arcutis Biotherapeutics reports a proposed sale of common stock. The filing lists 3,687 shares of common stock described under "Securities To Be Sold" with an effective date of 03/01/2026. The excerpt also shows a prior sale by Todd Edwards of 2,052 common shares on 02/02/2026.
Arcutis Biotherapeutics submitted a notice to sell 37,349 common shares under a Rule 144-type transaction tied to restricted stock vesting on 03/01/2026.
The filing identifies Todd F. Watanabe as a related address and reports 19,833 common shares sold during the prior three months (sale date shown 02/02/2026).
Arcutis Biotherapeutics filed a Form 144 to sell 2,853 shares of common stock. The filing lists the securities to be sold in connection with restricted stock vesting on 03/01/2026. The filing also shows 1,320 shares sold during the prior three months on 02/02/2026.
Arcutis Biotherapeutics proposes the sale of 6,287 common shares following restricted stock vesting on 03/01/2026. The filing lists recent open‑market sales by reporting person Patrick Burnett, including 11,500 shares on 12/15/2025 and 9,794 shares on 02/04/2026.
Arcutis Biotherapeutics filed a Form 144 notice reporting the intended sale of 39,272 common shares for $997,194.62, dated 03/02/2026. The filing also lists stock option exercises of 27,052 (06/14/2024) and 12,220 (05/31/2023).
Arcutis Biotherapeutics, Inc. reporting a Form 144 sale notification for 10,000 common shares to be sold on 03/02/2026 on NASDAQ. The filing notes prior sales by Howard Welgus of 10,000 shares on 01/02/2026 for $289,606.03 and 10,000 shares on 02/02/2026 for $250,482.69.
Arcutis Biotherapeutics filed a shelf registration statement to register multiple securities for potential future offerings. The prospectus covers common stock, preferred stock, debt securities, warrants, purchase contracts and units and permits selling securityholders to resell shares. The company states it will not receive proceeds from selling securityholders’ resales.
Arcutis Biotherapeutics (ARQT) is a commercial-stage dermatology-focused biopharmaceutical company centered on its topical PDE4 franchise ZORYVE and its biologic candidate ARQ-234. The company now markets four ZORYVE formulations across plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp/body psoriasis in the United States and Canada, with multiple pediatric label expansions and additional sNDAs planned.
Arcutis estimates an actively prescription-treated U.S. market of about 17 million topical patients across its core diseases and aims to position ZORYVE as a chronic, non-steroidal alternative to topical steroids, expanding from dermatology into primary care and pediatrics. Its strategy also includes life-cycle indication expansion (such as hidradenitis suppurativa and vitiligo), international licensing deals in Japan and Asia, and advancement of ARQ-234, a CD200R agonist being prepared for Phase 1 in atopic dermatitis with broader inflammatory potential.
Arcutis Biotherapeutics reported strong growth and a profitable fourth quarter 2025 while raising 2026 sales guidance. Q4 2025 net product revenue for ZORYVE was $127.5 million, up 84% year over year and 29% sequentially, driving total Q4 revenue to $129.5 million versus $71.4 million a year earlier.
Full-year 2025 net product revenue for ZORYVE reached $372.1 million, a 123% increase over 2024, with total revenue of $376.1 million. The company generated Q4 net income of $17.4 million, compared with a $10.8 million loss in Q4 2024, and narrowed its full-year net loss to $16.1 million from $140.0 million.
Arcutis produced $26.2 million of operating cash flow in Q4 and ended 2025 with $221.3 million in cash, cash equivalents, restricted cash, and marketable securities. It raised 2026 net product revenue guidance to a range of $480 million to $495 million and highlighted positive clinical progress and pipeline advancement for ZORYVE and ARQ-234.